RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9
Opus Genetics, Inc.
Opus Genetics, Inc. IRD | 0.00 |
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:
IRD) with a Outperform and lowers the price target from $10 to $9.
